Trial · NCT07912801
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
NCT07912801, Phase 4, Not yet recruiting, Peking University First Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery. Trials, record NCT07912801. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912801
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
- NCT number
- NCT07912801
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Peking University First Hospital
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Hypoxia-Inducible Factor 1, Alpha Subunit, Prolyl-Hydroxylase Inhibitors, Myocardial Ischemia, Myocardial Infarction Postoperative
- Interventions
- Roxadustat, Placebo
- First posted
- 2026-11-03
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants completing the trial intervention | Up to 30 days postoperatively. | Participants will be considered to have completed the trial intervention if they meet all of the following criteria: (1) they received the trial medication as randomized; (2) they underwent the scheduled high-sensitivity cardiac troponin I measurements during the perioperative period; and (3) they completed the 30-day postoperative follow-up. |
| Secondary | Recruitment rate | Screening and randomization period (before trial intervention). | Recruitment rate is defined as the proportion of eligible patients who provide written informed consent and undergo randomization. |
| Secondary | Peak hs-cTnI within 72 hours after surgery | Up to 72 hours after surgery. | Peak serum high-sensitivity cardiac troponin I (hs-cTnI) concentration within 72 hours after surgery |
| Secondary | Incidence of KDIGO stage 2 or 3 acute kidney injury within 7 days after surgery | Up to 7 days after surgery. | Stage 2 or 3 acute kidney injury will be diagnosed according to the KDIGO (Kidney Disease: Improving Global Outcomes) serum creatinine criteria. |
| Secondary | Incience of MACE within 30 days after surgery | Up to 30 days after surgery. | Major adverse cardiac events (MACE) are defined as a composite of myocardial infarction, stroke, ventricular arrhythmia requiring treatment, new-onset heart failure, reoperation, and cardiovascular death. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers34
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912801
GET https://conductscience.org/api/trials/v1/NCT07912801/papers?page=2